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Available online 1 October 2016The Staphylococcus aureus ﬁbrinogen binding MSCRAMM (Microbial Surface Components Recognizing Adhesive
Matrix Molecules), ClfA (clumping factor A) is an important virulence factor in staphylococcal infections and a
component of several vaccines currently under clinical evaluation. The mouse monoclonal antibody aurexis
(also called 12-9), and the humanized version teﬁbazumab are therapeutic monoclonal antibodies targeting
ClfA that in combination with conventional antibiotics were effective in animal models but showed less impres-
sive efﬁcacy in a limited Phase II clinical trial. We here report the crystal structure and a biochemical character-
ization of the ClfA/teﬁbazumab (Fab) complex. The epitope for teﬁbazumab is located to the “top” of the N3
subdomain of ClfA and partially overlaps with a previously unidentiﬁed second binding site for ﬁbrinogen. A
high-afﬁnity binding of ClfA to ﬁbrinogen involves both an interaction at the N3 site and the previously identiﬁed
docking of the C-terminal segment of the ﬁbrinogen γ-chain in the N2N3 trench. Although teﬁbazumab binds
ClfA with high afﬁnity we observe a modest IC50 value for the inhibition of ﬁbrinogen binding to theMSCRAMM.
This observation, pairedwith a common natural occurring variant of ClfA that is not effectively recognized by the
mAb, may partly explain the modest effect teﬁbazumab showed in the initial clinic trail. This information will
provide guidance for the design of the next generation of therapeutic anti-staphylococcal mAbs targeting ClfA.been deposited in Pr
pen access article und©2016 Published by Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Staphylococcus aureus (S. aureus) causes a number of opportunistic
infections that range from relatively benign skin infections to life-
threatening diseases including endocarditis, pneumonia and sepsis
(Kristinsson, 1989; Lowy, 1998). Clumping factor A (ClfA) is a ﬁbrino-
gen (Fg) binding microbial surface component recognizing adhesive
matrix molecules (MSCRAMM), and an important virulence factor of S.
aureus. ClfA plays a role in the molecular pathogenesis of several types
of experimental infections such as septic arthritis, infective endocarditis,
kidney abscesses and sepsis/septicemia (Flick et al., 2013; Josefsson et
al., 2001; McAdow et al., 2011; Sullam et al., 1996). Furthermore ClfA
is important for S. aureus colonization of biomaterials, which
presumably becomes coated with plasma proteins such as Fg onceotein Data
er the CC BY-Nimplanted (Vaudaux et al., 1995). ClfA binds to the carboxy terminal
of the γ-chain of Fg (McDevitt et al., 1995; McDevitt et al., 1997), a re-
gion that is important for platelet aggregation and coagulation
(Heemskerk et al., 2002; Jackson, 2007; Kamath et al., 2001) and recom-
binant ClfA has been reported to inhibit the interaction of Fg with the
platelet integrin αIIbβ3 (Liu et al., 2007; Liu et al., 2005). However, the
virulence potential of ClfA in a mouse model of septicemia does not ap-
pear to correlate with altered platelet aggregation or Fg coagulation but
rather seems to be a function of impaired bacterial clearance (Flick et al.,
2013). In fact ClfA can protect S. aureus against phagocytosis by macro-
phages (Palmqvist et al., 2004) and it appears that Fg binding to the
MSCRAMM is required for the ClfA mediated inhibition of phagocytosis
(Higgins et al., 2006). In addition, ClfA has been reported to bind com-
plement factor I. This interactionmay also play a role in ClfA dependent
resistance to bacterial clearance (Hair et al., 2010; Hair et al., 2008).
Due to the importance of ClfA as a virulence factor, the protein has
been explored as a potential vaccine candidate. Recombinant ClfA in-
duced an antibody response in mice (Josefsson et al., 2008) and mice
immunized with ClfA presented with less severe arthritis compared to
mice immunized with a control antigen (Josefsson et al., 2001).C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
329V.K. Ganesh et al. / EBioMedicine 13 (2016) 328–338Moreover, passive immunizationwith polyclonal ClfA antibodies gener-
ated in rats or rabbits protected mice against S. aureus induced sepsis
and arthritis (Josefsson et al., 2001). Recently, a multi-mechanistic
mAb targeting ClfA and the Alpha toxin was shown to be protective
against S. aureus infection in a mouse model (Tkaczyk et al., 2016). A
combination therapy of vancomycin with high titers of human poly-
clonal Abs or a mouse monoclonal antibody (mAb) called aurexis or
12-9 against ClfA was effective in a catheter induced infective endocar-
ditis model in rabbits where treating with vancomycin alone was less
effective (Patti, 2004; Vernachio et al., 2003;Weems et al., 2006). How-
ever, when teﬁbazumab, a humanized version of aurexis, was used to-
gether with antibiotics in a limited phase II clinical trial the results
were less impressive (Patti, 2004; Weems et al., 2006).
The domain organization of ClfA is prototypic for the MSCRAMM
subfamily of cell wall anchored staphylococcal proteins (Foster et al.,
2014). The N-terminus contains a signal sequence followed by the li-
gand-binding A region that is composed of three subdomains N1, N2
and N3. C-terminal of the A region is the serine-aspartate repeat (Sdr)
domain which can become glycosylated (Thomer et al., 2014;
Hazenbos et al., 2013) followed by the LPXTG motif and other features
required for cell wall anchoring. A segment composed of subdomains
N2 and N3 binds a peptide mimicking the C-terminus of Fg γ-chain
(γ-peptide) (McDevitt et al., 1997) and a segment containing amino
acids 229–545 of ClfA (ClfA229–545)was shown to represent theminimal
protein necessary for appreciable Fg binding (Ganesh et al., 2008).
Many of the staphylococcalMSCRAMMs appear to bind their ligands
by variations of the Dock, Lock and Latch (DLL) bindingmechanism (for
a recent review see Foster et al., 2014). This dynamic binding mecha-
nism was ﬁrst proposed after analyzing crystal structures of both the
apo (open) and the ligand-bound (closed) forms of the N2N3 ligand-
binding segment of the Staphylococcus epidermidis Fg-binding
MSCRAMM SdrG (Ponnuraj et al., 2003). Subsequent biochemical stud-
ies conﬁrmed the major steps of the DLL mechanism for SdrG (Bowden
et al., 2008). ClfAD327C/K541C (ClfACC) is a variant of ClfA that has a double
amino acid substitution to lock ClfA in the closed conformation through
formation of a disulﬁde bridge (Ganesh et al., 2008). While the corre-
sponding SdrGCC is unable to bind ligand due to the closure of the
docking trench, ClfACC surprisingly exhibits a higher afﬁnity for the Fg
γ-peptide than the wild-type ClfA229–545 (Ganesh et al., 2008). Subse-
quent structural and biochemical characterization revealed that ClfA
binds to Fg by a variant of the DLL mechanism where locking and
latching can precede ligand docking (Ganesh et al., 2008).
In order to understand the detailed mechanism of action of
teﬁbazumab, we used a combination of structural, biochemical and bio-
physical approaches to gain insight into the molecular details of the
mAb's interactionwith ClfA and the effects on theMSCRAMM's Fg bind-
ing.We determined the crystal structure of ClfACC in complexwith a Fab
fragment of teﬁbazumab. In the co-crystal structure, teﬁbazumab is
bound to the “top” of the N3 domain of ClfA. This mAb binding site is
distinct from the trench between N2 and N3 subdomains where the
Fg γ-peptide docks (Ganesh et al., 2008) and suggests that residues out-
side the docking trench on ClfA are also important for Fg binding. Fur-
ther biochemical studies demonstrate the presence of a second Fg
binding site on top of N3 that is critical for an overall high afﬁnity Fg/
ClfA interaction. These results reveal that teﬁbazumab inhibits ClfA
binding to Fg by targeting a previously unknown Fg binding site on
the MSCRAMM and provide additional target sites for future design of
effective inhibitors of the ClfA/Fg interaction.
2. Materials and Methods
2.1. Bacterial Strains, Plasmids and Primers
Amino acid substitutions in the teﬁbazumab epitope of ClfA were
generated in the plasmid pQE30 vector expressing ClfA229–545 from S.
aureus strain Newman (Ganesh et al., 2008) by site-directedmutagenesis using the primers listed in Supplementary Table ST6. Plas-
mid pCF41 (O'Connell et al., 1998) carrying DNA encoding ClfA221–559
served as template for introducing Y512A, P467A and W518A substitu-
tions. Overlapping complementary primers containing the desired nu-
cleotide changes (Supplementary Table ST6) were used to amplify the
plasmid.
The PCR reaction was incubated with 1 U of the restriction enzyme
DpnI (New England Biolabs) for 1 h at 37 °C to digest methylated DNA
used as template and transformed into E. coli TG1 (Zymo Research). E.
coli was grown at 37 °C in Luria-Bertani (LB) broth supplemented
with ampicillin (100 μg/ml, Sigma-Aldrich). Plasmids were extracted
with Wizard Plus SV Minipreps DNA puriﬁcation system (Promega)
and the mutation was conﬁrmed by DNA sequencing (Genewiz).
2.2. Recombinant Proteins
The recombinant proteins were expressed in E. coli Topp3 (Bayou
Biolabs) and puriﬁed by nickel chelate chromatography and anion ex-
change chromatography as previously described (Wann et al., 2000).
The GST tagged γ-peptide was expressed and puriﬁed as described ear-
lier (O'Connell et al., 1998). Proteins and peptide used in this study and
their speciﬁc names are listed in Supplementary Table ST1.
2.3. Fibrinogen
Human ﬁbrinogen (Catalog # FIB3, Enzyme Research Laboratories,
South Bend, IN) was used in all experiments and dialysed against
150 mM NaCl; 10 mM KCl; 25 mM Tris pH 7.4 (TBS buffer) unless pre-
pared as described. Fibrinogen D-fragment was purchased from
Millipore (Calbiochem, catalog #341600).
2.4. Generation of Fab Fragments
Puriﬁed teﬁbazumab (a generous gift of Inhibitex, Inc.) was dialyzed
against 20mMsodiumphosphate pH7.0 and adjusted to a ﬁnal concen-
tration of ~10 mg/ml. Beads containing immobilized papain (Thermo
Scientiﬁc, Rockford, IL) were washed 3 times with phosphate buffer
and a 50% slurrywasmadewith the digestion buffer, 20mMphosphate,
20 mM cysteine, 10 mM EDTA, pH 7.0. Five hundred μl of slurry was
added to 2 ml sample supplemented with 20 mM of cysteine and the
mixture was incubated for 8 h at 37 °C. The papain beads were then re-
moved by centrifugation and the digest was dialyzed against phosphate
buffer. Subsequently undigested IgG and generated Fc fragments were
removed by passing the mixture through a protein A column (Thermo
Scientiﬁc, Rockford, IL).
2.5. Crystallization, Structure Solution and Reﬁnement
The isolated Fab fragments were mixed with puriﬁed ClfACC at an
equal molar ratio and left for 1 h at 4 °C. The complex was then concen-
trated to ~10 mg/ml for crystallization experiments. Two microliters of
the sample was mixed with 2 μl of reservoir solution containing PEG
4000, 2% isopropanol, 0.1 M Hepes pH 7.0 and allowed to equilibrate
in a linbro plate at 4 °C. Several crystals were collected, washed 3
times with stabilizing solution, then dissolved and run on an SDS-page
gel to conﬁrm the presence of both proteins. The X-ray diffraction data
was collected at Advanced Photon Source at Argonne National laborato-
ry for 210° with an oscillation width of 1°. Data was processed using
HKL2000 (Otwinowski and Minor, 1997). The structure was solved by
the molecular replacement (MR) method using ClfACC (pdbid; 1VR3)
as the searchmodel. To determine theMR solution for the Fab fragment,
several poly-alanine models of Fv fragments from the PDB database
were attempted of which pdb id; 1F8T (Fokin et al., 2000) yielded a rea-
sonable MR solution. The model was rebuilt using Coot (Emsley and
Cowtan, 2004) and reﬁned using PHENIX (Adams et al., 2002) and
Refmac 5.0 (Murshudov et al., 1997) to a ﬁnal R-factor of 0.207 and an
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showed poor density and therefore backbone atoms were modeled
wherever possible. The data collection and reﬁnement statistics are
summarized in Table 1.
2.6. Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) experiments were carried out
using a VP-ITC instrument (MicroCal). In experiments where the inter-
action of soluble Fgwith ClfACCwas characterized the twoproteinswere
co-dialyzed against TBS. The titration was performed at 30 °C using a
preliminary injection of 5 μl followed by 29 injections of 10 μl with an
injection speed of 0.5 μl/s and a stirring speed of 260 rpm. The cell
contained 7 μM Fg (dimer concentration) and the syringe contained
150 μM ClfACC. Since Fg is a dimeric molecule, a single site binding
model with 14 μM concentration of Fg was used for data ﬁtting and an-
alyzed using Origin version 5 software (MicroCal).
For ClfAPWY/P16 peptide interaction, the protein was dialyzed and
the peptide dissolved in the binding buffer and 10 μl aliquots of
0.5 mM P16 peptide were injected into the cell containing 30 μM of
ClfAPWY.
2.7. Surface Plasmon Resonance
Surface plasmon resonance-based binding experiments were
performed at 25 °C on a Biacore 3000 (GE Healthcare/Biacore, Uppsa-
la, Sweden). Phosphate buffered saline (PBS-T: 8.06 mM Na2HPO4
and 1.94 mM KH2PO4 (pH 7.4), 2.7 mM KCl, 137 mM NaCl, and
0.005% Tween-20) was used as running buffer for immobilization
and binding experiments. A ﬂow rate of 5 μl/minwas used during im-
mobilization and a higher rate of 30 or 50 μl/min for binding experi-
ments. The sensor surfaces of Fg, D-fragment or ClfA proteins were
prepared on different sensor chips (CM5 for high density, CM3 for
medium density and C1 for low density ligand surfaces). The ligands
were covalently coupled to the chips using standard amine-coupling
chemistry. Frozen Fg stock (about 10 mg/ml in 20 mM sodium
citrate-HCl, pH 7.4) were thawed in a 37 °C water bath without any
agitation. After equilibrating to room temperature, Fg was diluted
in 10 mM sodium acetate (pH 5.5) to 10 or 20 μg/ml and injected
into an EDC/NHS activated ﬂow cell. The surface was deactivated
with ethanolamine. Fg D-fragment (5 μg/ml), ClfA229–545 and
ClfA221–559 (~20 μg/ml) were prepared in 10 mM sodium acetateTable 1
Crystallographic data measurement and reﬁnement data.
ClfA/Teﬁbazumab
Cell dimensions
a, b, c (Å) 234.2, 84.4, 48.0
β (°) 99.07
Space group C2
Max resolution (Å) 2.4
Reﬂections unique 36,373
Completeness (%) 99.5 (99)
Rmergea 0.09
Number of molecules in the asymmetric unit 1
Rfactor/Rfreeb 0.207/0.259
Average B value (Å) 66
No of non-hydrogen atoms 5551
ClfA 2393
Teﬁbazumab 2953
Water 205
Rms deviations from ideal values
Bond lengths (Å) 0.010
Bond Angles (°) 1.26
a Rmerge = Σ∣Ij− 〈I〉∣ / ΣIi; where Ij is the measured and 〈I〉 is the mean intensity of re-
ﬂection hkl.
b Rfree is calculated over 5% of randomly selected reﬂections not included in the
reﬁnement.(pH 5.0), ClfACC was prepared in 10 mM sodium acetate (pH 4.5) at
40 μg/ml for immobilization. A reference surface was made with ac-
tivation and deactivation steps but with no protein coupled. To pre-
pare a capturing surface for teﬁbazumab, about 1400 RU of F(ab’)2-
goat anti-human IgG Fc gamma antibody (Thermo Fisher Scientiﬁc
Catalog #31163) were immobilized on CM5 chip using 5 μg/ml of
F(ab’)2 in 10 mM sodium acetate pH 5.5. Teﬁbazumab was diluted
in PBS-T and captured by F(ab’)2, and another ﬂow cell with only
immobilized F(ab’)2 served as reference surface. For capturing the
GST fusion protein, approximately 11,000 RU of goat anti-GST anti-
body (GE Healthcare/Biacore) was immobilized on a CM5 chip. The
GST-tagged Fg γ peptide was captured by the antibody and created
a GST-γ ligand surface. Another ﬂow cell with immobilized anti-
GST antibody and captured GST was used a reference surface. To re-
generate the ligand surfaces, bound proteins were removed by a
1 min injection of 1 M NaCl for the Fg surface, 10 mM glycine
pH 2.6 for teﬁbazumab surface, and 0.01% SDS for the GST-γ surface.
All SPR responses were baseline corrected by subtracting the re-
sponse generated from the corresponding reference surface. Double-
referenced SPR response curves (with the buffer blank run further
subtracted)were used for afﬁnity determination. For steady-state inter-
action, the equilibrium response of each injection was collected and
plotted against the concentration of injected protein. A one-site binding
(hyperbola) model was ﬁtted to the data (GraphPad Prism 4, GraphPad
Software, Inc., La Jolla, CA, USA) to obtain the equilibrium dissociation
constant KD. Non-equilibrium data were globally ﬁtted to a 1:1
Langmuir binding model using BIAevaluation software (Version 4.1).
Association and dissociation rate constants ka1 and kd were obtained
from the ﬁtting, and the dissociation constant KD was derived (KD =
kd / ka). Errors are reported as standard error of mean from two or
more experiments.
3. Results
3.1. Teﬁbazumab Binds to Different Forms of ClfA and Partially Inhibits the
Binding of ClfA to Fibrinogen
The mAb 12-9 (also called aurexis) was raised in mice using
ClfA221–559 from S. aureus strain Newman as the antigen and was
shown via SPR analysis to bind strongly to the A domain ClfA40–559
with a reported dissociation constant KD of 0.21 nM (rate constants
ka = 1.99 × 106 M−1 s−1 and kd = 4.18 × 10−4 s−1) (Hall et al.,
2003). We recorded very similar binding parameters for 12-9's
interaction with ClfA221–559 with a KD of 0.25 nM (rate constants;
ka = 2.28 × 106 M−1 s−1 and kd = 5.71 × 10−4 s−1, Fig. S1A). Earlier
structural and biochemical studies showed that two shorter variants
of ClfA covering residues 229–545 called ClfA229–545 and ClfACC, re-
spectively, also effectively bound to Fg (Ganesh et al., 2008). In
ClfACC two Cys residues (D327C/K541C) have been introduced to
form a disulﬁde bond and keep the latch in the latching trench.
Since the N2N3 subdomain orientation of ClfA221–559 and ClfACC are
different as revealed by the corresponding crystal structures
(Deivanayagam et al., 2002; Ganesh et al., 2008) we compared the
binding of teﬁbazumab (the humanized form of aurexis) to different
forms of ClfA N2N3. As shown in Fig. S1B & C, teﬁbazumab binds to all
three forms of ClfA (ClfA221–559, ClfA229–545 and ClfACC) in a very
similar manner, and it can inhibit the binding of ClfA229–545 to Fg or
Fg D-fragment.
Using the same SPR technique, we characterized the binding of
teﬁbazumab to ClfA229–545 and ClfA221–559, (see Supplementary Table
ST1 for detailed descriptions of the proteins). The results show that
compared to the original mouse mAb 12-9, teﬁbazumab bound to
ClfA229–545 with a somewhat weaker afﬁnity; KD of 0.79 ± 0.03 nM
(ka = 5.94 ± 0.26 × 105 M−1 s−1 and kd = 4.90 ± 0.14 × 10−4 s−1;
Fig. 1A). The almost four-fold decrease in afﬁnity is mainly due to a
slower on-rate, while the off-rate is similar with the two forms of
Fig. 1. SPR analysis of the ligand interactions and inhibitions. (A) Two-fold serial dilution of ClfA229–545 (from32 to 1 nM)were injected to a teﬁbazumab surface (~150 RU capturedby goat
anti-human IgG (Fc) polyclonal F(ab’)2). SPR sensorgrams shown inblackwereﬁtted to a 1:1 Langmuir bindingmodel curves shown in red. The derived dissociation constant KD (0.81 nM)
was calculated from the rate constants (ka = 5.94 × 105M−1 s−1 and kd= 4.90 × 10−4 s−1). (B) ClfA229–545 (from 1.28 to 0.04 μM)was injected to a Fg surface (10,000 RU on CM5 chip).
The average responses at steady state (shown in red)were plotted as a function of the ClfA229–545 concentration and ﬁt to a one-site binding (hyperbola) model (inset). KD of 0.66 μMwas
determined. (C & D) Dose response for the inhibition of different concentrations (from 0.125 to 4 μM) of teﬁbazumab (C) or Fg (D) on 1 μM of ClfA229–545 binding to immobilized Fg. The
maximum 100% response is ClfA229–545 binding without any inhibitors and shown as dashed lines. (E) Inhibition data from C&D were plotted against inhibitor concentrations (the
monomer Fg concentration was used) and ﬁtted to a four-parameter logistic function. The control is for the binding response without any inhibitor. The teﬁbazumab IC50 measured for
inhibiting ClfA229–545 binding to Fg is 0.39 μM and the ﬁtted minimum is 27%, the Fg IC50 is 0.48 μM and the ﬁtted minimum is 0%. The binding of the inhibitors (at the highest
concentration of 4 μM) to the Fg surface were very small (b10 RU), compared to the ClfA response of ~550 RU, so they were not subtracted from the total responses.
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teﬁbazumab is conﬁned within the N2N3 subdomain and is present in
all our recombinant forms of this region.
We then examined teﬁbazumab's ability to inhibit ClfA binding to Fg.
Even though teﬁbazumab binds ClfA229–545 with ~800-fold higher afﬁn-
ity (lower KD) than Fg (KD values of 0.79± 0.03 nM vs. 0.61 ± 0.05 μM,
Fig. 1A & B), the mAb's ability to inhibit ClfA229–545 binding to
immobilized Fg is relatively weak, with an IC50 of 0.33 ± 0.06 μM (Fig.
1C & E), only marginally better than that observed for soluble Fg's inhi-
bition of ClfA binding to immobilized Fg (IC50= 0.43± 0.05 μM, Fig. 1D
& E). Furthermore, while soluble Fg could completely inhibit ClfA229–545
binding to immobilized Fg, therewas about 25% of the Fg/ClfA229–545 in-
teraction that teﬁbazumab could not block (Fig. 1 C, D & E). These data
indicate that teﬁbazumab binds ClfA strongly but does not efﬁciently
or completely neutralize the Fg binding activity of ClfA.
3.2. Overall Structure of the ClfA/Teﬁbazumab Fab Complex
To uncover the structural basis for the ability of teﬁbazumab to in-
hibit ClfA binding to Fg and to determine the epitope on ClfA recognized
by themAbwe attempted to crystallize a Fab fragment in complex with
ClfACC (which is more stable than our other recombinant forms of ClfA
N2N3). The Fab fragment of teﬁbazumab was generated by digesting
the mAb with immobilized papain and cleared by passing the digestthrough an immobilized protein A column to remove undigested Abs
and Fc containing antibody fragments. Different crystallization screens
were initially performed for the MSCRAMM/Fab fragment. The condi-
tions described in Materials and Methods were used to generate rela-
tively large crystals suitable for X-ray analyses. The crystals diffracted
X-rays to a 2.4 Å resolution and the structure of the complexwas solved
by the molecular replacement method. The data collection and reﬁne-
ment statistics are summarized in Table 1.
The overall structure of the complex is shown in Fig. 2A. As expected,
ClfACC was found in the latched, closed form due to the presence of the
engineered disulﬁde bond. The overall structure of ClfA in the complex
is similar to the structure observed in the ClfACC/Fg γ-peptide complex
(Ganesh et al., 2008) with an rms deviation of 0.62 Å for 302 Cα atoms.
The teﬁbazumab Fab binds only to the ClfA N3 domainmaking it un-
likely that themAb could affect N2-N3 subdomain orientations (Fig. 2A)
consistent with the SPR data showing that Teﬁbazumab (Fig. S1B) binds
equallywell to ClfA221–559 and ClfACC. Furthermore, the overall structure
of the N3 subdomain in the Fab/ClfACC complex is very similar to the
structures of the N3 subdomain in other ClfA structures and show rms
deviations of 0.4 Å and 0.3 Å with the apo-ClfA221–559 (Deivanayagam
et al., 2002) and ClfACC/Fgγ-peptide (Ganesh et al., 2008) structures, re-
spectively. Thus the binding of the Fab fragment to ClfACC does not seem
to induce anymajor conformational change in the MSCRAMM. Further-
more, teﬁbazumab binds on “top” of the N3 subdomain of ClfA where
Fig. 2. ClfA-teﬁbazumab interactions. (A) The structure of disulﬁde bond-closed ClfACC in
complex with the Fab fragment of teﬁbazumab. ClfACC N2 and N3 domains are shown in
green and yellow, respectively. The light and the heavy chains of the Fab fragment are
shown in magenta and cyan, respectively. (B) Hydrogen bonding and key interactions
between ClfA and the light chain of teﬁbazumab. Hydrogen bonds are shown as dashed
lines. ClfA residues are shown in yellow and light chain residues are shown in magenta.
(C) Hydrogen bonding and key interactions between ClfA and the heavy chain of
teﬁbazumab. Hydrogen bonds are shown as dotted lines. ClfA residues are shown in
yellow and heavy chain residues are shown in cyan.
332 V.K. Ganesh et al. / EBioMedicine 13 (2016) 328–338themAbwould not affect the redirection of theN3C-terminal extension
in ClfA221–559 including the locking and latching events. These conclu-
sions are consistent with the experimental data showing that the mAb
binds to the closed form of ClfACC. The Fab/MSCRAMM complex in
total buries a solvent associable area of 2118 Å2 (ClfA: 1007 Å2, Fab:
1111 Å2) with the heavy chain burying more surface area than the
light chain. The residues in the ClfA N3 domain buried by teﬁbazumab
binding are shown in Supplementary Table ST2.
3.3. The Teﬁbazumab Epitope: The ClfA/Fab Light Chain Interaction
The interaction of ClfA with the light chain of teﬁbazumab is primar-
ily hydrophilic in nature and is shown in Fig. 2B. In total nine hydrogen
bonds (b3.2 Å cut off distance) help stabilize the light chain/ClfACC in-
teractions (Fig. 2B). These hydrogen bonds are listed in Supplementary
Table ST3. The long CDR1 of the light chain makes extensive contact
with ClfA with eight hydrogen bond interactions. Tyr31(OH) (CDR1) is
involved in two hydrogen bonds with the backbone atoms of
Ile433(N) and Thr431(O) of ClfA. Ser33 (CDR1) interacts with
Ile433(O) and Lys434(NZ) while Lys36, and Tyr38 (CDR1) interact
with carbonyl oxygens of Asn460 and Thr464 in ClfA, respectively. In
addition, Lys434(NZ) and Asn460(OD1) of ClfA contact the backbone
atoms of CDR1 residues Ser33(O) and Asn34(O), respectively, through
hydrogen bonds. The interaction with CDR3 is less extensive with one
backbone-backbone hydrogen bond between Phe466 (ClfA) and
Leu98 (CDR3). There is no contact between CDR2 of the light chain
and ClfA within 4.0 Å cut-off distance. A list of all residues in ClfA and
Teﬁbazumab Fab making contact (within a 4 Å cut off distance) is pre-
sented in Supplementary Table ST4.
3.4. The Teﬁbazumab Epitope: The ClfA/Fab Heavy Chain Interaction
The interaction between ClfA and the heavy chain of teﬁbazumab is
predominantly hydrophobic in nature with six hydrogen bonds (b3.2 Å
cut off distance) between the heavy chain and ClfA (Supplementary
Table ST3). A view of the ClfA/Fab heavy chain interactions is shownin Fig. 2C. The side chains of Tyr512 and Asp481 of ClfA form hydrogen
bonds with residues in the CDR1 targeting the backbone carbonyl oxy-
gen “O” of Ser30 and the side chain of Arg31(NH1), respectively. The
Trp518(NE1) and Asn468(ND2) form hydrogen bonds with the CDR2
residues Asn56(OD1) and Asn468(ND2). In addition, Asn477 and
Asn463 participate in hydrogen bonds with the backbone oxygen (O)
of Phe101 and Gly104, respectively. Surface exposed Trp518 of ClfA
stacks with the backbone of Gly54 of the heavy chain. Trp52 of CDR2
docks in a hydrophobic pocket formed by Val411, Trp518 and Tyr510
of ClfA. In addition, a signiﬁcant number of hydrophobic residues that
are surface exposed in the apo structure of ClfA aremasked by the inter-
actionwith the Fab.Masking of this large patch of a hydrophobic surface
could be responsible for the high afﬁnity that teﬁbazumab shows for
ClfA.
3.5. Biochemical Characterization of the Teﬁbazumab Epitope
To conﬁrm the structural model of the ClfA/teﬁbazumab complex
derived from the diffraction data we made several amino acid substitu-
tions in the ClfA N3 domain at the teﬁbazumab epitope (Fig. 3A) and
evaluated the effects of the substitutions on the overall ClfA-
teﬁbazumab interaction.We found that changing Tyr512 in the F-strand
of the N3 subdomain to Ala (Y512A) resulted in a slightly reduced bind-
ing to teﬁbazumab, while a triple mutant (ClfAPWY) comprising P467A,
Y512A and W518A substitutions almost completely abolished
teﬁbazumab binding to ClfA221–559 (Fig. 3B). Since all these three resi-
dues are surface exposed their substitutions should not cause gross
structural changes to the protein. Circular dichroism spectroscopy
(Fig. S2) indicates that ClfAPWY is properly folded with a similar second-
ary structure composition as that of ClfA221–559.
3.6. The Teﬁbazumab/ClfA Complex Structure Implicates a Second Site Re-
quired for High Afﬁnity Fibrinogen Binding to the MSCRAMM
Superposition of the ClfACC/Fg γ-peptide ligand complex and the
ClfA/teﬁbazumab Fab inhibitor complex is shown in Fig. 3D. The peptide
binding site is located between the N2 and the N3 subdomains and ex-
tends along the “G” strand of N3while the teﬁbazumab epitope is found
on “top” of N3 (Fig. 3D and E) and does not overlap with the peptide
binding site. Thus we are left with an apparent paradox where
teﬁbazumab effectively inhibits the ClfA/Fg interaction but the Fg γ-
peptide binding site and the teﬁbazumab epitope do not overlap. Is it
possible that the interaction of ClfA with Fg extends beyond the C-ter-
minal section of the Fg γ-chain and that ClfA makes additional contacts
with Fg? In support of a more complex Fg/ClfA binding mechanism we
have found that a synthetic Fg γ-peptide, even at high concentrations,
can only reduce Fg binding to the MSCRAMM by a maximum of ~50%
(Geoghegan et al., 2010). Teﬁbazumab may inhibit ClfA binding to Fg
by blocking a potential second binding site. Four additional pieces of ev-
idence support a binding model with at least two contact sites between
Fg and ClfA.
3.6.1. Molecular Modeling of ClfA/Fg D-fragment
The possibility of multiple contacts between ClfA and Fg was ﬁrst
evaluated by molecular modeling studies. As teﬁbazumab inhibits ClfA
binding to both Fg and the D-fragment in an almost identical way
(Fig. S1C), and the afﬁnity of ClfA for Fg and the D-fragment are very
similar (Fig. 4C), it is likely that all the contacts between ClfA and Fg in-
volve only the D-fragment. We therefore used the crystal structures of
the Fg D-fragment (Pdb id: 2H43 (Doolittle et al., 2006)) and ClfACC
(Ganesh et al., 2008) for the modeling studies. The 17-residue C-termi-
nal segment of the Fg γ-chain, which binds to ClfA in the N2N3 trench,
corresponds to a disordered region and cannot be detected in the crystal
structure of the ~80 kDa Fg D-fragment. Rigid body docking of the Fg D-
fragment on ClfACC resulted in a model of the ClfA/D-fragment complex
where the orientation of the C-terminal residue (His400) of the Fg γ-
Fig. 3.Analysis of ClfA N3 site interactionswith teﬁbazumab and ﬁbrinogen. (A) Ribbon diagramof ClfA N3 domain showing alanine substitutions at the positions of P467, Y512 andW518
in blue. The Fg γ-peptide is shown as a red ribbon. (B) Biacore sensorgrams showing 0.1 μM of ClfA221–559 wt or variants run over immobilized teﬁbazumab and ﬁbrinogen. The variant
proteins used are indicated in panel A. (C) ClfAPWY and Fg-γ P16 synthetic peptide interactionmeasured by ITC. Thermodynamic parameters values (KD= 5.8 μM, ΔH=−6.79 kcal/mol,
ΔS=1.6 cal/mol/K) are derived from this experiments. (D) Overlay of crystal structures of ClfACC/Fgγ-peptide and the ClfACC/teﬁbazumab Fab complex. The N2 and theN3 subdomains of
ClfA and Fab complex are shown in green and yellow respectively and ClfA from the Fgγ-peptide complex (PDB: 2VR3) is shown in grey. Teﬁbazumab light and heavy chains are shown in
magenta and cyan, respectively, and the Fg γ-peptide bound in the N2N3 trench is shown as a red ribbon. Note that the N2N3 site and the mAb epitope do not overlap. (E) Molecular
surface representation of ClfA shown in green (N2 domain), yellow (N3 domain). The surface that contacts Fg γ-peptide and the light chain and heavy chains of teﬁbazumab are
shown in red, gold and grey, respectively. (F) Molecular model of ClfA/Fg D-fragment interaction. ClfA N2 and N3 domains are colored green and yellow, respectively. The α, β, and γ
chains of Fg D-fragment are shown in orange, light blue and red, respectively.
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idue (Leu392) of the Fg γ-peptide in the ClfA/peptide structure. Molec-
ular modeling showed that the docking of the C-terminal of the Fg γ-
chain in the trench between the N2 and N3 subdomains could place
the 30 kDa γ-globular module of the D-fragment close to the top face
of the N3 domain of ClfA (Fig. 3F). In this model there is a substantial
contact area between the D-fragment and the N3 domain of ClfA. Thus
it is clear from the model that a second binding site located on “top”
of the N3 domain of ClfA is sterically possible when the Fg γ-peptide
is docked in the N2N3 trench.
3.6.2. Recombinant ClfA Domains Bind to Intact Fg or the Fg D-fragment
With Signiﬁcantly Higher Afﬁnities Than to the Fg γ-peptide
Abindingmechanism involvingmultiple contact sites in Fgwith ClfA
should result in a signiﬁcant higher afﬁnity of the MSCRAMM for full-
length Fg compared to the Fg γ-peptide. An ITC experiment where
ClfACC was titrated into a cell containing full-length Fg gave a KD of
0.3 μM (Fig. 4A) whereas titrating a synthetic C-terminal γ-chainpeptide into a cell containing ClfACC gave a KD of 6.2 μM (Fig. 4B). The
20-fold higher afﬁnity observed for full-length Fg is consistent with a
model involving additional contacts between ClfA N2N3 and intact Fg
beyond the Fg γ-peptide region and that these second site interactions
contribute to the overall higher afﬁnity.
SPR experiments where ClfA229–545 was run over chips containing
immobilized intact Fg, Fg D-fragment or GST-γ showed about a 50-
fold difference in KD for binding of the MSCRAMM to the Fg γ-peptide
and the Fg or Fg D-fragment, respectively (Fig. 4C, Supplementary
Table ST5). On the other hand, the KD values for ClfA binding to intact
Fg or Fg D-fragment are very similar; 0.56 μM for Fg compared to
0.75 μM for the Fg D-fragment (Fig. 4C). Since most of the known and
putative Fg interactive sites in ClfA are locatedwithin theN3 subdomain
we examined the interactions of a recombinant form of N3 (ClfA370–559)
to the different forms of immobilized Fg. ClfAN3 bound to all forms of Fg
(Fig. 4D, Supplementary Table ST5). TheKD values for ClfAN3 binding to
Fg or the Fg D-fragment were similar and about 10 fold higher than the
KD values measured for ClfA229–545 binding to the same proteins. The Fg
Fig. 4. Comparison of ClfA-Fg interactions. (A& B) Analysis of the interaction using ITC. Fgwas placed in the cell and ClfACC was titrated in A, whereas ClfACCwas placed in the cell and P16
was titrated in B. (C) SPRmeasurement of the interactions between ClfA229–545 and Fg molecules. Two-fold dilution of ClfA229–545 (1.28 to 0.04 μM, 8.0 to 0.125 μM, and 32 to 1 μM)were
injected to Fg (600 RU), D-fragment (700 RU) and GST-γ (1500 RU) respectively. (D) SPRmeasurement of the interactions between ClfAN3 and Fgmolecules. Two-fold dilution of ClfAN3
(12.8 to 0.1 or 0.4 μM) were injected to Fg (1000 RU), D-fragment (1000 RU) and GST-γ (2500 RU) respectively. SPR sensorgrams for binding at different concentration of proteins are
shown as black lines. The average responses at steady state (shown in red) were used to generate a binding curve (inset) and the equilibrium dissociation constant KD was determined.
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for intact Fg or the Fg D-fragment. Taken together the results of these
binding studies are consistent with our model proposing a second Fg
binding site in ClfA and further suggest that all sites in Fg targeting the
MSCRAMM are located in the D-fragment.
3.6.3. Amino Acid Substitutions in the Teﬁbazumab Epitope in ClfA Affect Fg
but not Fg γ-peptide Binding to the MSCRAMM
We propose that teﬁbazumab inhibits the binding of ClfA to Fg by
competing for the second Fg binding site on the MSCRAMM. If this
model is correct, substitution of residues in the teﬁbazumab epitope
may affect Fg binding to ClfA. Consequently, we examined the Fg bind-
ing of ClfA proteins (ClfAY512A and ClfAPWY) that were affected in mAb
binding (Fig. 3A). SPR analysis using immobilized human Fg showed
that the ClfAY512A exhibited reduced binding to Fg (Fig. 3B). The effect
of the Y512A substitution was much more pronounced when Fg rather
than teﬁbazumab was the ligand indicating that Tyr512 plays a more
important role for Fg binding than for mAb binding. The triple mutant
ClfAPWY completely lost its ability to bind teﬁbazumab and showedmin-
imal binding to Fg (Fig. 3B).Furthermore our bindingmodel predicts that substitution of the res-
idues located on top of the N3 domain would not affect the binding of
ClfA to the Fg γ-peptide. We used ITC to explore if the ClfAPWY mutant
has retained the ability to bind the Fg γ-peptide P16 (Fig. 3C). P16 is a
17 amino acid long Fg γ-peptide that contains one residue substitution
(Asp to Ala at the 16th position of the γ-peptide) and binds ClfA with a
higher afﬁnity compared to a corresponding peptide with a wild type
sequence (Ganesh et al., 2008). P16 bound ClfAPWY with a similar
afﬁnity (KD = 5.8 μM) to that previously recorded for P16 binding to
ClfA221–545 (KD=3.0 μM) (Ganesh et al., 2008). In addition, SPR analysis
of ClfAPWY binding to Fg and the D-fragment, respectively, indicated KD
values in the low micromolar range (10 μM and 17 μM, respectively,
data not shown) comparable to the Fg γ-peptide binding to ClfA
(4.3 μM, Fig. 3F). These results suggest that the Dock, Lock and Latch
mechanism of Fg binding remains intact in the ClfAPWY mutant and
that ClfAPWY speciﬁcally lost the second Fg binding site.
3.6.4. Teﬁbazumab Does Not Inhibit the Fg γ-peptide binding to ClfA
If teﬁbazumab affect Fg binding only at the second site, but not in the
N2N3 trench,wewould not expect binding of the Fgγ-peptide to ClfA to
Fig. 5. Effect of teﬁbazumab on ClfA binding to immobilized GST-γ. (A) SPR experiments for 5 μMClfA229–545 binding to GST-γ surface (700 RU, captured by anti-GST pAb), in the presence
(dashed line,with the teﬁbazumabbackground response subtracted) or absence (solid line) of 2 μMteﬁbazumab. (B) Taking advantage of the slowoff-rate of ClfACC (5 μM)binding toGST-
γ (black line), strong binding of 2 μM of teﬁbazumab to the GST-γ bound ClfACC was shown (in green), compared to non-speciﬁc binding of teﬁbazumab (2 μM, in blue) to the GST-γ.
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ysis of teﬁbazumab-mediated inhibition of ClfA221–545 binding to
immobilized GST-tagged Fg γ-peptide (GST-γ). ClfA221–545 could still
bind to GST-γ in the presence of teﬁbazumab (Fig. 5). In fact the re-
sponse is higher in the presence of the mAb, which likely reﬂects thatFig. 6. ClfA229–545 and some natural variants binding to teﬁbazumab and Fg. (A) Sensorgram
teﬁbazumab (~200 RU captured through goat anti-human IgG (Fc) polyclonal F(ab’)2). Disso
with ﬁtting are shown in Supplementary Figure S3. (B) Binding of 320 nM of each protein
interactions is listed. Standard errors for the KD measurements from different experiments (n ≥a teﬁbazumab: ClfA221–545 complex is formed and bind to the
immobilized GST-γ. To demonstrate that ClfA can simultaneously bind
to the Fgγ-peptide and themAbwe took advantage of the relatively sta-
ble interaction between ClfACC and GST-γ, shown by a slower dissocia-
tion phase in the SPR curve (Fig. 5B). In this system the GST-γ bounds generated by binding of each ClfA protein at 32 nM concentration to the surface of
ciation constants KD for each ClfA/teﬁbazumab interaction are listed, and sensorgrams
to the immobilized Fg (about 600 RU) are overlaid and the KD for each of the ClfA/Fg
2).
336 V.K. Ganesh et al. / EBioMedicine 13 (2016) 328–338ClfACC was still able to bind teﬁbazumab. Thus teﬁbazumab did not in-
hibit ClfA binding to GST-γ, while the mAb could inhibit ClfA221–545
binding to Fg (about 70%, Fig. 1D&E) and D-fragment (about 80%, Fig.
S1C).
Taken together these results demonstrate that teﬁbazumab inhibits
Fg binding by blocking a second binding site located at the top of the
N3 domain which is distinct from the Fg γ-peptide binding site located
in the trench between the N2N3 subdomains. A schematic diagram
representing the regions of Fg and teﬁbazumab binding to ClfA and
the mechanism of teﬁbazumab's partial inhibition of Fg binding to the
MSCRAMM is shown in Fig. 7.
4. Discussion
The crystal structure of ClfA N2N3 in complex with the Fab fragment
generated from teﬁbazumabdeﬁnes the epitope for this inhibitingmAb,
which to our surprise is located on top of the N3 subdomain. Through
biochemical studies we demonstrate that the teﬁbazumab epitope par-
tially overlaps with a second Fg binding site, which is required for high
afﬁnity binding of Fg to ClfA. A substantial variation in the amino acid
sequence of the identiﬁed teﬁbazumab epitope is apparent from exam-
ining ClfA sequences available in the public domain (Supplementary
Table ST2). To evaluate the signiﬁcance of these variationswe expressed
four of the more common teﬁbazumab epitope isoforms and deter-
mined their relative binding to immobilized teﬁbazumab by SPR. One
of these isoforms (ClfAN463R) where Asn is replaced by the bulky
charged residue Arg, showed a 60-fold reduced afﬁnity for the mAb
(KD = 0.7 nM (ClfA229–545) to KD = 45 nM (ClfAN463R) (Fig. 6A). Inter-
estingly, this variant appears to have maintained its high afﬁnity for Fg
(Fig. 6B). These results demonstrate that teﬁbazumab recognizes some
but not all naturally occurring ClfA variants of S. aureus. In addition,Fig. 7. Schematic representation of the binding and inhibition mechanism of Fg and teﬁbazum
disulﬁde bonds linking the individual α, β, and γ chains and the dimeric Fg molecule are sho
in orange, light blue and red respectively. The N2 and the N3 subdomains in ClfA are colored g
ClfA and the teﬁbazumab epitope. Teﬁbazumab can only partially inhibit Fg binding to ClfA byteﬁbazumab cannot completely block Fg binding to ClfA and although
the recorded KD for the mAb's binding to ClfA is low it is not quite as
low as that demonstrated for the corresponding mouse mAb before
being “humanized” (Fig. 1). Furthermore, the observed IC50 is rather
high (Fig. 1), which may be a consequence of the complex Fg binding
mechanism employed by ClfA. Taken together these propertiesmay ex-
plain the modest effect of teﬁbazumab as an anti-staphylococcal thera-
py in humans (Weems et al., 2006).
Our earlier study showed that ClfA binding to Fg involves a vari-
ant of the Dock, Lock and Latch mechanism where the C-terminus
of the Fg γ-chain docks in a trench formed between the N2 and N3
subdomains of the MSCRAMM (Ganesh et al., 2008). In the current
report we demonstrate that the high afﬁnity interaction of ClfA
with intact Fg involves additional contacts between the MSCRAMM
and the ligand protein. These additional interactions increase the
overall afﬁnity of the interaction and appear to involve residues in
the γ-globular domain of the γ-chain of Fg that can be brought into
close contact and interact with the “top” of the N3 domain according
to our modeling experiments.
Is it possible that this complex, multi-contact binding mecha-
nism here shown for the ClfA/Fg interaction, also applies to other
ligand/MSCRAMM interactions. The Fg binding MSCRAMMs
FnBPA (Wann et al., 2000), FnBPB (Burke et al., 2011) of S. aureus
and Fbl of S. lugdunensis (Geoghegan et al., 2010) all target the C-
terminus of the Fg γ-chain using N2N3 segments with similar
subdomain organization to ClfA. Thus Fg binding to these
MSCRAMMs could also involve additional binding sites. A synthetic
peptide corresponding to the linear sequence in Fg targeted by the
related protein ClfB binds to theMSCRAMMwith rather low afﬁnity
and the peptide is a poor inhibitor of Fg binding to ClfB
(unpublished data). To account for the much higher afﬁnity seenab respectively to ClfA. (A) Domain organization of ﬁbrinogen and ClfA. The inter chain
wn as black lines. The α, β, and γ chain regions corresponding to D-fragment are shown
reen and yellow respectively. (B) A schematic model showing the Fg binding regions on
competing for the second Fg binding site on the MSCRAMM.
337V.K. Ganesh et al. / EBioMedicine 13 (2016) 328–338with intact Fg, ClfB like ClfA, may provide additional interactive
sites outside the N2N3 trench. The Fg-binding MSCRAMM SdrG
binds to a 15 amino acid linear Fg sequence in a rather high afﬁnity
interaction (Ponnuraj et al., 2003). In this case it is possible that ad-
ditional sites are not required for an overall high afﬁnity, although
preliminary modeling experiments suggest that additional con-
tacts are possible. Thus, although the DLL binding mechanism
seems to be involved in most MSCRAMM ligand interactions addi-
tional contacts may be required for high afﬁnity interactions. Fur-
thermore, it is possible that sequence variations in the MSCRAMM
at the second binding site could affect the afﬁnity for Fg and thus
the virulence potential of the ClfA variant. It is also possible that
amino acid variations in human Fg sequences targeting the second
site may bind with different afﬁnities to the MSCRAMM and conse-
quently affect the susceptibility of an individual to staphylococcal
infections.
It should be pointed out that the study reported here has been
conducted with a segment of ClfA and it is unclear if Fg binding to
the full-length MSCRAMM can involve even more extensive inter-
actions outside the N2N3 sub-domains. Our studies with
teﬁbazumab have also revealed a novel inhibitory mechanism for
the binding of ClfA to Fg. It is clear that the mechanism by which
ClfA binds Fg is much more complex than previously appreciated
and this complexity can at least partly explain the difﬁculty in gen-
erating effective anti-ClfA therapeutic agents including mAbs that
can efﬁciently recognize natural ClfA variants from different
strains of S. aureus. However, further characterization of the second
binding site(s) may provide the opportunity to design antibodies
and other molecules that interfere with both Fg-binding sites on
ClfA to effectively inhibit this interaction that appears to be critical
for S. aureus virulence (Josefsson et al., 2008).Conﬂicts of Interest
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